Ryan G. Walker

Ryan G. Walker

Auto-generated profile, based on publicly available information

Ryan G. Walker

From the Departments of Molecular Genetics, Biochemistry and Microbiology and

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Circulation Research
Verified
Journal Article
Closed access
PDF file
RWRyan G. Walker
Ryan G. Walker
TPTommaso Poggioli
Tommaso Poggioli
LKLida Katsimpardi
Lida Katsimpardi
SBSean M. Buchanan
Sean M. Buchanan
JOJuhyun Oh
Juhyun Oh
RLRichard T. Lee
Richard T. Lee
Growth differentiation factor 11 (GDF11) and myostatin (or GDF8) are closely related members of the transforming growth factor β superfamily and are often perceived to serve similar or overlapping roles. Yet, despite commonalities in protein sequence, receptor utilization and signaling, accumulating evidence suggests that these 2 ligands can have distinct functions in many situations. GDF11 is essential for mammalian development and has been suggested to regulate aging of multiple tissues, whereas myostatin is a well-described negative regulator of postnatal skeletal and cardiac muscle mass and modulates metabolic processes. In this review, we discuss the biochemical regulation of GDF11 and myostatin and their functions in the heart, skeletal muscle, and brain. We also highlight recent clinical findings with respect to a potential role for GDF11 and/or myostatin in humans with heart disease. Finally, we address key outstanding questions related to GDF11 and myostatin dynamics and signaling during development, growth, and aging.

8 January 2016 in Circulation Research
Verified
Journal Article
Closed access
PDF file
TPTommaso Poggioli
Tommaso Poggioli
Ana VujicAna Vujic
Ana Vujic
PYPeiguo Yang
Peiguo Yang
CMClaudio Macias-Trevino
Claudio Macias-Trevino
AUAysu Uygur
Aysu Uygur
RLRichard T. Lee
Richard T. Lee
Rationale:: Growth differentiation factor 11 (GDF11) and GDF8 are members of the transforming growth factor-β superfamily sharing 89% protein sequence homology. We have previously shown that circulating GDF11 levels decrease with age in mice. However, a recent study by Egerman et al reported that GDF11/8 levels increase with age in mouse serum. Objective:: Here, we clarify the direction of change of circulating GDF11/8 levels with age and investigate the effects of GDF11 administration on the murine heart. Methods and Results:: We validated our previous finding that circulating levels of GDF11/8 decline with age in mice, rats, horses, and sheep. Furthermore, we showed by Western analysis that the apparent age-dependent increase in GDF11 levels, as reported by Egerman et al, is attributable to cross-reactivity of the anti-GDF11 antibody with immunoglobulin, which is known to increase with age. GDF11 administration in mice rapidly activated SMAD2 and SMAD3 signaling in myocardium in vivo and decreased cardiac mass in both young (2-month-old) and old (22-month-old) mice in a dose-dependent manner after only 9 days. Conclusions:: Our study confirms an age-dependent decline in serum GDF11/8 levels in multiple mammalian species and that exogenous GDF11 rapidly activates SMAD signaling and reduces cardiomyocyte size. Unraveling the molecular basis for the age-dependent decline in GDF11/8 could yield insight into age-dependent cardiac pathologies.

3 March 2017 in BMC Biology
Verified
Journal Article
Open access
PDF file
RWRyan G. Walker
Ryan G. Walker
MCMagdalena Czepnik
Magdalena Czepnik
EGErich J. Goebel
Erich J. Goebel
JMJason C. McCoy
Jason C. McCoy
Ana VujicAna Vujic
Ana Vujic
TTThomas B. Thompson
Thomas B. Thompson
Growth/differentiation factor 8 (GDF8) and GDF11 are two highly similar members of the transforming growth factor β (TGFβ) family. While GDF8 has been recognized as a negative regulator of muscle growth and differentiation, there are conflicting studies on the function of GDF11 and whether GDF11 has beneficial effects on age-related dysfunction. To address whether GDF8 and GDF11 are functionally identical, we compared their signaling and structural properties. Here we show that, despite their high similarity, GDF11 is a more potent activator of SMAD2/3 and signals more effectively through the type I activin-like receptor kinase receptors ALK4/5/7 than GDF8. Resolution of the GDF11:FS288 complex, apo-GDF8, and apo-GDF11 crystal structures reveals unique properties of both ligands, specifically in the type I receptor binding site. Lastly, substitution of GDF11 residues into GDF8 confers enhanced activity to GDF8. These studies identify distinctive structural features of GDF11 that enhance its potency, relative to GDF8; however, the biological consequences of these differences remain to be determined.

13 November 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
JMJohn Melchior
John Melchior
RWRyan G Walker
Ryan G Walker
ACAllison L Cooke
Allison L Cooke
JMJamie Morris
Jamie Morris
MCMark Castleberry
Mark Castleberry
WDW Sean Davidson
W Sean Davidson
Apolipoprotein A-I (apoA-I) is the scaffold protein that is essential for the assembly and function of HDL particles. A structural model for monomeric, lipid-free apoA-I, based on previous and new data, is now presented. Apolipoprotein (apo)A-I is an organizing scaffold protein that is critical to high-density lipoprotein (HDL) structure and metabolism, probably mediating many of its cardioprotective properties. However, HDL biogenesis is poorly understood, as lipid-free apoA-I has been notoriously resistant to high-resolution structural study. Published models from low-resolution techniques share certain features but vary considerably in shape and secondary structure. To tackle this central issue in lipoprotein biology, we assembled a team of structural biologists specializing in apolipoproteins and set out to build a consensus model of monomeric lipid-free human apoA-I. Combining novel and published cross-link constraints, small-angle X-ray scattering (SAXS), hydrogen–deuterium exchange (HDX) and crystallography data, we propose a time-averaged model consistent with much of the experimental data published over the last 40 years. The model provides a long-sought platform for understanding and testing details of HDL biogenesis, structure and function.

1 March 2014 in Endocrinology
Verified
Journal Article
Open access
PDF file
BRBuel D. Rodgers
Buel D. Rodgers
BWBenjamin D. Wiedeback
Benjamin D. Wiedeback
KHKnut E. Hoversten
Knut E. Hoversten
MJMelissa F. Jackson
Melissa F. Jackson
RWRyan G. Walker
Ryan G. Walker
TTThomas B. Thompson
Thomas B. Thompson
The immortal C2C12 cell line originates from dystrophic mouse thigh muscle and has been used to study the endocrine control of muscle cell growth, development, and function, including those actions regulated by myostatin. Previous studies suggest that high concentrations of recombinant myostatin generated in bacteria inhibit C2C12 proliferation and differentiation. Recombinant myostatin generated in eukaryotic systems similarly inhibits the proliferation of primary myosatellite cells, but consequently initiates, rather than inhibits, their differentiation and is bioactive at far lower concentrations. Our studies indicate that 2 different sources of recombinant myostatin made in eukaryotes stimulate, not inhibit, C2C12 proliferation. This effect occurred at different cell densities and serum concentrations and in the presence of IGF-I, a potent myoblast mitogen. This stimulatory effect was comparable to that obtained with TGFβ1, a related factor that also inhibits primary myosatellite cell proliferation. Attenuating the myostatin/activin (ie, Acvr2b) and TGFβ1 receptor signaling pathways with the Alk4/5 and Alk5 inhibitors, SB431542 and SB505142, respectively, similarly attenuated proliferation induced by serum, myostatin or TGFβ1 and in a dose-dependent manner. In serum-free medium, both myostatin and TGFβ1 stimulated Smad2 phosphorylation, but not that of Smad3, and a Smad3 inhibitor (SIS3) only inhibited proliferation in cells cultured in high serum. Thus, myostatin and TGFβ1 stimulate C2C12 proliferation primarily via Smad2. These results together question the physiological relevance of the C2C12 model and previous studies using recombinant myostatin generated in bacteria. They also support the alternative use of primary myosatellite cells and recombinant myostatin generated in eukaryotes.

1 March 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RWRyan G. Walker
Ryan G. Walker
EAElizabeth B. Angerman
Elizabeth B. Angerman
CKChandramohan Kattamuri
Chandramohan Kattamuri
YLYun-Sil Lee
Yun-Sil Lee
SLSe-Jin Lee
Se-Jin Lee
TTThomas B. Thompson
Thomas B. Thompson
Background: GASP-1 and GASP-2 are highly specific antagonists for the TGF- ligand myostatin, a negative regulator of muscle growth. Results: GASP-1 and GASP-2 form asymmetric and symmetric complexes with myostatin, respectively. Conclusion: Despite the different binding modes, the GASP proteins retain a high specificity for myostatin. Significance: Inhibition of myostatin can be achieved using different binding modes and may facilitate future development of novel anti-myostatin therapeutics. Myostatin, a member of the TGF- family of ligands, is a strong negative regulator of muscle growth. As such, it is a prime therapeutic target for muscle wasting disorders. Similar to other TGF- family ligands, myostatin is neutralized by binding one of a number of structurally diverse antagonists. Included are the antagonists GASP-1 and GASP-2, which are unique in that they specifically antagonize myostatin. However, little is known from a structural standpoint describing the interactions of GASP antagonists with myostatin. Here, we present the First low resolution solution structure of myostatin-free and myostatin-bound states of GASP-1 and GASP-2. Our studies have revealed GASP-1, which is 100 times more potent than GASP-2, preferentially binds myostatin in an asymmetrical 1:1 complex, whereas GASP-2 binds in a symmetrical 2:1 complex. Additionally, C-terminal truncations of GASP-1 result in less potent myostatin inhibitors that form a 2:1 complex, suggesting that the C-terminal domains of GASP-1 are the primary mediators for asymmetric complex formation. Overall, this study provides a new perspective on TGF- antagonism, where closely related antagonists can utilize different ligand-binding strategies.